Liposomal Paclitaxel With HER-2 Blockers Shows Strong Real-World Results in Advanced Breast Cancer
A real-world study of 526 patients found that paclitaxel liposome combined with anti-HER-2 targeted therapies delivered median overall survival of ...
A real-world study of 526 patients found that paclitaxel liposome combined with anti-HER-2 targeted therapies delivered median overall survival of ...
A new Cell Research study shows that BCR-ABL1 forms liquid-like phase-separated condensates inside leukemic cells that physically slow tyrosine kinase ...
A meta-analysis of 39 randomized controlled trials involving 8,399 cancer patients found that early palliative care significantly improves quality of ...
A new review maps how Chinese cancer research has evolved from single-target molecular reductionism toward a three-tier holistic integrative medicine ...
A retrospective study of nearly 1,600 patients finds that HER2-low breast cancer behaves like HER2-0 disease in metastatic timing and ...
Two landmark New England Journal of Medicine studies show the pan-RAS inhibitor daraxonrasib nearly doubles survival in previously treated metastatic ...
A study of 10,556 Brazilian prostate cancer patients found 87.7 percent five-year cancer-specific survival, with older age, lower education and ...
A new commentary argues that exceptional long-term responses to melflufen-dexamethasone in myeloma case reports should not override subgroup trial evidence ...
A sweeping analysis of more than 21,500 FDA adverse event reports has mapped which anticancer drugs most strongly trigger hand-foot ...
A study of 124 patients shows second-generation tunneled peritoneal catheters provide durable symptom relief for malignant ascites with a manageable ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine